WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Dapiglutide

Governed registry record

3 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. Dapiglutide, a dual GLP-1 and GLP-2 receptor agonist, for obesity: a randomised, double-blind, placebo-controlled parallel-group, proof-of-concept trial.

    DOI: 10.1016/j.eclinm.2026.103801

    Source identity and connection checked by Codex (AI).

  2. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel.

    DOI: 10.1002/jpen.2286

    Source identity and connection checked by Codex (AI).

  3. The dual GLP-1 and GLP-2 receptor agonist dapiglutide promotes barrier function in murine short bowel.

    DOI: 10.1111/nyas.14791

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Reiner J
  • Thiery J
  • Held J
  • Berlin P
  • Skarbaliene J
  • Vollmar B
  • Jaster R
  • Eriksson PO
  • Lamprecht G
  • Witte M
  • Griffin J
  • Russell W
  • Berner-Hansen M
  • Ehlers L
  • Nielsen CK
  • Pálsson TG
  • Forman JL
  • Lukacova M
  • Jensen BAH
  • Mathiesen DS
  • Englund A
  • Gether IM
  • Johansen NJ
  • Pedersen MG
  • Hartmann B
  • Holst JJ
  • Knop FK
  • Lund AB